Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: Case report
Poddubskaya E. V., Baranova M. P., Allina D. O., Sekacheva M. I., Makovskaia L. A., Kamashev D. E`., Suntsova M. V., Barbara V. S., Kochergina-Nikitskaya I. N., Aleshin A. A.
Cold Spring Harbor Molecular Case Studies
Vol.5, Issue2, Num.a003434
Опубликовано: 2019
Тип ресурса: Статья
Аннотация:
Ovarian cancer is the fifth leading cause of cancer-related female mortality and the most lethal gynecological cancer. In this report, we present a rare case of recurrent granulosa cell tumor (GCT) of the ovary. We describe the case of a 26-yr-old woman with progressive GCT of the right ovary despite multiple lines of therapy who underwent salvage therapy selection based on a novel bioinformatical decision support tool (Oncobox). This analysis generated a list of potentially actionable compounds, which when used clinically lead to partial response and later long-term stabilization of the patient's disease. © 2019 Poddubskaya et al.
Ключевые слова:
antineoplastic agent; bleomycin; cisplatin; DNA; etoposide; filachromine; forkhead box protein L2; imatinib; RNA; sorafenib; unclassified drug; imatinib; adult; Article; cancer growth; case report; clinical article; clinical decision support system; colitis; cystadenoma; cytoreductive surgery; DNA extraction; drug substitution; drug withdrawal; female; gene expression profiling; granulosa cell tumor; human; human tissue; image analysis; liver tumor; medical history; nuclear magnetic resonance imaging; operative blood loss; ovary polycystic disease; patient satisfaction; pelvis tumor; peritoneal biopsy; peritoneum metastasis; personalized medicine; polyarthritis; prescription; rare disease; RNA extraction; salpingooophorectomy; salvage therapy; spleen tumor; treatment refusal; treatment response; tumor volume; ultrasound; whole exome sequencing; granulosa cell tumor; treatment outcome; tumor recurrence; Adult; Female; Granulosa Cell Tumor; Humans; Imatinib Mesylate; Neoplasm Recurrence,
Язык текста: Английский
ISSN: 2373-2873
Poddubskaya E. V. Elena Vladimirovna 1965-
Baranova M. P.
Allina D. O.
Sekacheva M. I. Marina Igorevna 1976-
Makovskaia L. A.
Kamashev D. E`. Dmitrij E`duardovich 1964-
Suntsova M. V. Mariya Vladimirovna 1986-
Barbara V. S.
Kochergina-Nikitskaya I. N.
Aleshin A. A.
Поддубская Е. В. Елена Владимировна 1965-
Баранова М. П.
Аллина Д. О.
Секачева М. И. Марина Игоревна 1976-
Маковскаиа Л. А.
Камашев Д. Э. Дмитрий Эдуардович 1964-
Сунцова М. В. Мария Владимировна 1986-
Барбара В. С.
Кочергина-Никицкайа И. Н.
Алешин А. А.
Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: Case report
Текст визуальный непосредственный
Cold Spring Harbor Molecular Case Studies
Vol.5, Issue2 Num.a003434
2019
Статья
antineoplastic agent bleomycin cisplatin DNA etoposide filachromine forkhead box protein L2 imatinib RNA sorafenib unclassified drug imatinib adult Article cancer growth case report clinical article clinical decision support system colitis cystadenoma cytoreductive surgery DNA extraction drug substitution drug withdrawal female gene expression profiling granulosa cell tumor human human tissue image analysis liver tumor medical history nuclear magnetic resonance imaging operative blood loss ovary polycystic disease patient satisfaction pelvis tumor peritoneal biopsy peritoneum metastasis personalized medicine polyarthritis prescription rare disease RNA extraction salpingooophorectomy salvage therapy spleen tumor treatment refusal treatment response tumor volume ultrasound whole exome sequencing granulosa cell tumor treatment outcome tumor recurrence Adult Female Granulosa Cell Tumor Humans Imatinib Mesylate Neoplasm Recurrence,
Ovarian cancer is the fifth leading cause of cancer-related female mortality and the most lethal gynecological cancer. In this report, we present a rare case of recurrent granulosa cell tumor (GCT) of the ovary. We describe the case of a 26-yr-old woman with progressive GCT of the right ovary despite multiple lines of therapy who underwent salvage therapy selection based on a novel bioinformatical decision support tool (Oncobox). This analysis generated a list of potentially actionable compounds, which when used clinically lead to partial response and later long-term stabilization of the patient's disease. © 2019 Poddubskaya et al.